ArticleBMJ open2025

Aumolertinib in combination with Lastet in the first-line treatment of EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (EVOLUTION): protocol for a single-arm, phase II clinical trial.

Jianing Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.